FP
FPH.AU Fisher & Paykel Healthcare Corporation Ltd
- Market cap
- AUD 22.4B
- P/E
- 54.5x
- P/B
- 13.29x
- ROE
- 22.1%
- Dividend yield
- 1.14%
- Fundamental score
- 3.2/5
Ratios use the latest price and the fiscal year ending Mar 2026.
Is FPH.AU undervalued?
Graham numberThe Graham number of Fisher & Paykel Healthcare Corporation Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fisher & Paykel Healthcare Corporation Ltd fundamental analysis
14 of 22 checks passedROE 2/2
High return on equity (22.1%), above 20%.
ROA 1/1
Return on assets (16.4%) is above the industry median (-35.3%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (25.0%) is above the 5-year average (-2.5% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (25.0%) is above the industry median (24.9%).
Revenue Growth 2/2
Revenue grew 14.0% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (6.9%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 64.8x against interest expense, well covered.
PE vs Market 0/1
PE (54.5x) is above the market median (15.0x).
PE vs Industry 0/1
PE (54.5x) is above the industry median (36.4x).
PBV 0/1
Price to book (13.3x) is above the industry median (4.0x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 724.0, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
Dividend yield (1.0%) is in the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 53.9%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Fisher & Paykel Healthcare Corporation Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fisher & Paykel Healthcare Corporation Ltd
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. The company provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. It also offers adult respiratory products, including airvo system, optiflow na…
Full company profileFisher & Paykel Healthcare Corporation Ltd financial statements
Fisher & Paykel Healthcare Corporation Ltd annual financial statements (NZD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 797M | 907M | 1.03B | 1.23B | 1.97B | 1.68B | 1.59B | 1.74B | 2.02B | 2.36B |
| Gross Profit | 518M | 596M | 689M | 819M | 1.12B | 939M | 885M | 1.04B | 1.27B | 1.51B |
| Operating Income | 193M | 248M | 300M | 377M | 712M | 506M | 332M | 353M | -371M | 672M |
| EBITDA | 278M | 317M | 340M | 438M | 808M | 602M | 434M | 466M | 654M | 832M |
| Net Income | 169M | 190M | 209M | 287M | 524M | 377M | 250M | 133M | 377M | 472M |
| EPS | 0.29 | 0.33 | 0.36 | 0.50 | 0.91 | 0.65 | 0.43 | 0.23 | 0.64 | 0.80 |
| Balance Sheet | ||||||||||
| Total Assets | 805M | 964M | 1.16B | 1.39B | 1.91B | 1.95B | 2.06B | 2.28B | 2.55B | 2.87B |
| Total Liabilities | 198M | 248M | 282M | 447M | 510M | 396M | 422M | 523M | 660M | 744M |
| Shareholders' Equity | 606M | 716M | 877M | 943M | 1.40B | 1.56B | 1.64B | 1.76B | 1.89B | 2.13B |
| Cash & Short-term Investments | 75.5M | 142M | 135M | 140M | 347M | 290M | 121M | 82.0M | 265M | 464M |
| Total Debt | 59.3M | 80.6M | 85.6M | 133M | 116M | 104M | 146M | 189M | 153M | 147M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 177M | 233M | 243M | 311M | 575M | 300M | 223M | 430M | 549M | 668M |
| Capital Expenditure | 57.7M | 92.8M | 128M | 171M | 185M | 170M | 211M | 339M | 103M | 174M |
| Free Cash Flow | 120M | 140M | 115M | 140M | 390M | 131M | 11.6M | 90.6M | 446M | 494M |
| Ratios | ||||||||||
| ROE | 27.9% | 26.6% | 23.9% | 30.5% | 37.5% | 24.2% | 15.3% | 7.5% | 20.0% | 22.1% |
| ROA | 21.0% | 19.7% | 18.1% | 20.7% | 27.5% | 19.3% | 12.1% | 5.8% | 14.8% | 16.4% |
| Net Profit Margin | 21.2% | 21.0% | 20.3% | 23.3% | 26.6% | 22.4% | 15.8% | 7.6% | 18.7% | 20.0% |
| Debt to Equity | 0.10x | 0.11x | 0.10x | 0.14x | 0.08x | 0.07x | 0.09x | 0.11x | 0.08x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Fisher & Paykel Healthcare Corporation Ltd dividends
- Dividend yield
- 1.14%
- Forward dividend
- 0.44 AUD
- Payout ratio
- 53.9%
- Ex-dividend date
- Jun 22, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | NZD 254M | 0.43 | 53.9% |
| 2025 | NZD 196M | 0.33 | 51.9% |
| 2024 | NZD 146M | 0.25 | 109.7% |
| 2023 | NZD 196M | 0.34 | 78.2% |
| 2022 | NZD 225M | 0.39 | 59.7% |
| 2021 | NZD 181M | 0.31 | 34.6% |
| 2020 | NZD 146M | 0.25 | 51.0% |
| 2019 | NZD 115M | 0.20 | 54.8% |
| 2018 | NZD 103M | 0.18 | 53.9% |
| 2017 | NZD 89.4M | 0.16 | 52.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Sep 27, 2004.
Who owns Fisher & Paykel Healthcare Corporation Ltd
- Insiders 3.69%
- Institutions 38.65%
- Public & others 57.67%
- Shares outstanding 588M
- Free float 585M
Top funds holding FPH.AU
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard International Stock Index-Total Intl Stock Indx | 8.75M | 1.52% | - | Oct 2020 |
| Price (T.Rowe) International Discovery Fund | 5.37M | 0.93% | - | Jan 2021 |
| Smallcap World Fund | 4.72M | 0.82% | - | Dec 2020 |
| Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 3.62M | 0.63% | - | Dec 2020 |
| Invesco Oppenheimer International Small-Mid Company Fund | 2.85M | 0.49% | - | Jan 2021 |
| New Perspective Fund Inc | 2.70M | 0.47% | - | Dec 2020 |
| iShares Core MSCI EAFE ETF | 2.61M | 0.45% | - | Feb 2021 |
| American Funds Insurance Ser-Global Growth Fund | 2.55M | 0.44% | - | Dec 2020 |
| Columbia Acorn International Fund | 2.01M | 0.35% | - | Dec 2020 |
| iShares MSCI Eafe ETF | 1.90M | 0.33% | - | Feb 2021 |
Fisher & Paykel Healthcare Corporation Ltd company profile
- Company name
- Fisher & Paykel Healthcare Corporation Ltd
- Ticker
- FPH.AU
- ISIN
- NZFAPE0001S2
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 7,357
- Fiscal year end
- March
- Address
- 15 Maurice Paykel Place, Auckland, New Zealand, 2013
- Phone
- 64 9 574 0100
- Website
- fphcare.com
About Fisher & Paykel Healthcare Corporation Ltd
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. The company provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. It also offers adult respiratory products, including airvo system, optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation. In addition, the company provides infant respiratory products, such as resuscitation, invasive ventilation, continuous positive airway pressure (CPAP), and nasal high flow products. Further, it offers hospital products comprising humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, and humidifiers. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.
Fisher & Paykel Healthcare Corporation Ltd management
10- Mr. Lewis G. GradonMD, CEO & Executive Director · born 1961
- Ms. Lyndal YorkChief Financial Officer
- Mr. Andy NiccolChief Operating Officer
- Dr. Andrew SomervellVice President of Products & Technology
- Mr. Daniel AdolphHead of Investor Relations
- Ms. Raelene LeonardCompany Secretary & General Counsel
- Ms. Karen KnottGeneral Manager of Corporate Communications
- Mr. Justin CallahanVP of Sales & Marketing
- Ms. Nicola TalbotVice President of Human Resources
- Mr. Jonathan RhodesVice President ? Network Design, Facilities, Infrastructure & Sustainability